Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 6
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN)
Oliver Illini, Maximilian J Hochmair, Hannah Fabikan, Christoph Weinlinger, Amanda Tufman, Aurélie Swalduz, Kristina Lamberg, Sayed M. S. Hashemi, Florian Huemer, Anders Vikström, Katja Mohorčič
Izvirni znanstveni članek
Oznake: podatki iz resničnega življenja;selperactinib;tarčna terapija;zaviralci tirozinskih kinaz;real-world data;selpercatinib;targeted therapy;tyrosine kinase inhibitor;
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Metho ...
Leto: 2021 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Angela Märten, Tanja Čufer
Izvirni znanstveni članek
Oznake: osimertinib;raziskava GioTag;GioTag study;
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osi ...
Leto: 2020 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC
Alfredo Addeo, Maximilian J Hochmair, Urška Janžič, Elizabeth Dudnik, Andriani Charpidou, Adam Płużański, Tudor Ciuleanu, Ivan Shterev Donev, Judith Elbaz, Jørgen Aarøe, René Ott, Nir Peled
Izvirni znanstveni članek
Oznake: napredovali nedrobnocelinčni karcinom pljuč;podatki iz resničnega življenja;srednja Evropa;advanced non-small cell lung cancer;real-world data;Central Europe;
Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with adv ...
Leto: 2021 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Angela Märten, Tanja Čufer
Izvirni znanstveni članek
Oznake: osimertinib;raziskava GioTag;GioTag study;
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease foll ...
Leto: 2019 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
Oliver Illini, Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Tanja Čufer, Katja Mohorčič, Maximilian J Hochmair
Izvirni znanstveni članek
Oznake: podatki iz resničnega življenja;capmatinib;tarčna terapija;real-world data;targeted therapy;
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population i ...
Leto: 2022 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Maximilian J Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Čufer
Izvirni znanstveni članek
Oznake: non-small-cell lung cancer;afatinib;osimertinib;epidermal growth factor receptor;EGFR;observational study;
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positiv ...
Leto: 2018 Vir: Digitalni repozitorij raziskovalnih organizacij Slovenije
Št. zadetkov: 6
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: